A prospective nested case–control study conducted by Nicholas P. McAndrew et al. in 2021 [31] on 1287 BC patients investigated the impact of inflammation on the relapse in early BC treated with aromatase inhibitors (AIs) in the adjuvant setting. Here, CYP19A1 is linked to breast cancer.